GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » Gross Margin %

Kura Oncology (Kura Oncology) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Kura Oncology's Gross Profit for the three months ended in Mar. 2024 was $0.00 Mil. Kura Oncology's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Kura Oncology's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Kura Oncology's Gross Margin % or its related term are showing as below:


KURA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.88
* Ranked among companies with meaningful Gross Margin % only.

Kura Oncology had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Kura Oncology was 0.00% per year.


Kura Oncology Gross Margin % Historical Data

The historical data trend for Kura Oncology's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kura Oncology Gross Margin % Chart

Kura Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kura Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kura Oncology's Gross Margin %

For the Biotechnology subindustry, Kura Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's Gross Margin % falls into.



Kura Oncology Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Kura Oncology's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Kura Oncology's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Kura Oncology  (NAS:KURA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Kura Oncology had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Kura Oncology Gross Margin % Related Terms

Thank you for viewing the detailed overview of Kura Oncology's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kura Oncology (Kura Oncology) Business Description

Traded in Other Exchanges
Address
12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Executives
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas Malley director C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas James Doyle officer: SVP, Finance & Accounting C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kirsten Flowers officer: Chief Commercial Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kathleen Ford officer: Chief Operating Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale officer: Chief Medical Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Teresa Brophy Bair officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer director 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Troy Edward Wilson director, officer: President and CEO C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Marc Grasso officer: CFO, CBO C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell officer: Acting Chief Medical Officer C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Antonio Gualberto officer: Chief Medical Officer 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142